US7252829B1
(en)
*
|
1998-06-17 |
2007-08-07 |
Idm Pharma, Inc. |
HLA binding peptides and their uses
|
EP0793501A4
(en)
*
|
1994-12-14 |
2000-05-03 |
Scripps Research Inst |
In vivo activation of tumor-specific cytotoxic t cells
|
US6514942B1
(en)
*
|
1995-03-14 |
2003-02-04 |
The Board Of Regents, The University Of Texas System |
Methods and compositions for stimulating T-lymphocytes
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US8038994B2
(en)
|
1996-05-15 |
2011-10-18 |
Quest Pharmatech Inc. |
Combination therapy for treating disease
|
KR20020011137A
(en)
*
|
1996-05-15 |
2002-02-07 |
리차드 이. 바글레이 |
Method and composition for reconforming multi-epitopic antigens to initiate an immune response
|
US20080220012A1
(en)
*
|
1996-05-15 |
2008-09-11 |
Ragupathy Madiyalakan |
Therapeutic Compositions that alter the immune response
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
ATE397061T1
(en)
|
1997-01-08 |
2008-06-15 |
Invitrogen Corp |
METHOD FOR PRODUCING PROTEINS
|
US20040202680A1
(en)
*
|
1997-01-30 |
2004-10-14 |
O'hagan Derek |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
US6884435B1
(en)
*
|
1997-01-30 |
2005-04-26 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
ATE235890T1
(en)
*
|
1997-01-30 |
2003-04-15 |
Chiron Corp |
USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE DEFENSE
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
CA2330212A1
(en)
*
|
1998-05-08 |
1999-11-18 |
Sloan-Kettering Institute For Cancer Research |
Compositions and methods for active vaccination
|
GB9810040D0
(en)
*
|
1998-05-11 |
1998-07-08 |
Univ Nottingham |
Blood borne tumour markers
|
EA004107B1
(en)
*
|
1998-08-11 |
2003-12-25 |
Айдек Фармацевтикалс Корпорэйшн |
Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
|
US6573043B1
(en)
*
|
1998-10-07 |
2003-06-03 |
Genentech, Inc. |
Tissue analysis and kits therefor
|
BR9915164A
(en)
*
|
1998-11-09 |
2003-01-07 |
Idec Pharma Corp |
Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
|
WO2000027433A1
(en)
*
|
1998-11-09 |
2000-05-18 |
Idec Pharmaceuticals Corporation |
Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
|
US6541214B1
(en)
*
|
1998-11-13 |
2003-04-01 |
Oregon Heath Science University |
N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
|
GB9827228D0
(en)
|
1998-12-10 |
1999-02-03 |
Univ Nottingham |
Cancer detection method and reagents
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
US7625859B1
(en)
*
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
US7396810B1
(en)
*
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
EP1146789B1
(en)
|
1999-01-27 |
2009-03-18 |
Cornell Research Foundation, Inc. |
Treating cancers associated with overexpression of her-2/neu
|
US7198920B1
(en)
*
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
ATE474048T1
(en)
*
|
1999-01-29 |
2010-07-15 |
Corixa Corp |
HER2/NEU FUSION PROTEINS
|
CA2367692A1
(en)
*
|
1999-03-15 |
2000-09-21 |
Introgen Therapeutics, Inc. |
Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
|
EP1754488A1
(en)
|
1999-05-24 |
2007-02-21 |
Introgen Therapeutics, Inc. |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
WO2000071577A1
(en)
*
|
1999-05-25 |
2000-11-30 |
Human Genome Sciences, Inc. |
Meth1 and meth2 polynucleotides and polypeptides
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
MXPA01013395A
(en)
*
|
1999-06-25 |
2003-09-04 |
Genentech Inc |
TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES.
|
US7060284B1
(en)
|
1999-08-03 |
2006-06-13 |
The Ohio State University |
Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
KR20090126330A
(en)
|
1999-08-27 |
2009-12-08 |
제넨테크, 인크. |
Dosages for treatment with anti-erbb2 antibodies
|
US20030157119A1
(en)
*
|
1999-09-22 |
2003-08-21 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
AU7710300A
(en)
*
|
1999-09-22 |
2001-04-24 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
AU7743100A
(en)
*
|
1999-09-30 |
2001-04-30 |
Corixa Corporation |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
US7378096B2
(en)
|
1999-09-30 |
2008-05-27 |
Health Research, Inc. |
Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
|
FR2801106B1
(en)
*
|
1999-11-12 |
2007-10-05 |
Commissariat Energie Atomique |
METHOD FOR DIAGNOSING AN ATNC STRAIN-INDUCED TEST IN A BIOLOGICAL SAMPLE AND ITS USE IN THE DIFFERENTIAL DIAGNOSIS OF DIFFERENT ATNC STRAINS
|
JP2003530083A
(en)
*
|
1999-12-10 |
2003-10-14 |
エピミューン インコーポレイテッド |
Induction of a Cellular Immune Response to HER2 / neu Using Peptide and Nucleic Acid Compositions
|
AU2744201A
(en)
*
|
1999-12-29 |
2001-07-09 |
Corixa Corporation |
Murine neu sequences and methods of use therefor
|
AU2001234493A1
(en)
*
|
2000-01-21 |
2001-07-31 |
Corixa Corporation |
Compounds and methods for prevention and treatment of her-2/neu associated malignancies
|
US6528060B1
(en)
*
|
2000-03-16 |
2003-03-04 |
Genzyme Corporation |
Therapeutic compounds
|
CA2403964C
(en)
|
2000-03-30 |
2013-04-30 |
Dendreon Corporation |
Compositions and methods for dendritic cell-based immunotherapy
|
AU2001252262B2
(en)
*
|
2000-04-13 |
2006-02-02 |
Biolife Science Forschungs-und Entwicklungsgesellschaft m.b.H |
Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells
|
AU2001259271A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
DE60139768D1
(en)
|
2000-05-19 |
2009-10-15 |
Genentech Inc |
GENERAL PROCESS FOR IMPROVING THE PROBABILITY OF AN EFFECTIVE RESPONSE TO A K
|
US10293056B1
(en)
|
2000-05-24 |
2019-05-21 |
Board Of Regents, The University Of Texas System |
Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
|
US20030232399A1
(en)
*
|
2000-06-14 |
2003-12-18 |
Robertson John Forsyth Russell |
Cancer detection methods and reagents
|
FR2812087B1
(en)
*
|
2000-07-21 |
2007-05-11 |
Inst Nat Sante Rech Med |
METHOD OF SCREENING PEPTIDES USED IN IMMUNOTHERAPY
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
AU2001283360A1
(en)
*
|
2000-08-14 |
2002-02-25 |
Corixa Corporation |
Methods for diagnosis and therapy of hematological and virus-associated malignancies
|
AU2001295008A1
(en)
*
|
2000-08-14 |
2002-02-25 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of Her-2/neu-associated malignancies
|
ES2377077T3
(en)
|
2000-10-18 |
2012-03-22 |
Glaxosmithkline Biologicals S.A. |
Vaccines comprising the MAGE antigen bound to a protein D fragment
|
JP2005500247A
(en)
*
|
2000-12-07 |
2005-01-06 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システム |
Treatment for human MDA-7
|
US20040121946A9
(en)
*
|
2000-12-11 |
2004-06-24 |
John Fikes |
Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US7507724B2
(en)
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
CA2438754C
(en)
*
|
2001-02-20 |
2014-10-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
A cell therapy method for the treatment of tumors
|
US20040071671A1
(en)
*
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
ES2394293T3
(en)
*
|
2001-02-28 |
2013-01-30 |
Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. |
Vaccine against cancers that are associated with the HER-2 / neu oncogene
|
ES2502366T3
(en)
|
2001-03-09 |
2014-10-03 |
Board Of Regents, The University Of Texas System |
Induction of tumor immunity by folate-binding protein variants
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
JP4608210B2
(en)
|
2001-05-31 |
2011-01-12 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
Chimeric alphavirus replicon particles
|
ATE345812T1
(en)
*
|
2001-09-03 |
2006-12-15 |
Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh |
ANTIGEN MIMOTOPES AND VACCINES AGAINST CANCER
|
EP1438583B1
(en)
|
2001-09-20 |
2009-09-16 |
Board of Regents, The University of Texas System |
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
|
CA2477780A1
(en)
*
|
2002-03-05 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Methods of enhancing immune induction involving mda-7
|
US8802618B2
(en)
*
|
2002-03-08 |
2014-08-12 |
Board Of Regents, The University Of Texas System |
Controlled modulation of amino acid side chain length of peptide antigens
|
WO2003086041A2
(en)
*
|
2002-04-11 |
2003-10-23 |
Altarex Medical Corporation |
Binding agents and their use in targeting tumor cells
|
WO2004000102A2
(en)
*
|
2002-06-19 |
2003-12-31 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
US9200036B2
(en)
|
2002-07-12 |
2015-12-01 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
US20090110702A1
(en)
|
2002-07-12 |
2009-04-30 |
The Johns Hopkins University |
Mesothelin Vaccines and Model Systems and Control of Tumors
|
AU2003259109A1
(en)
|
2002-07-12 |
2004-02-02 |
The Johns Hopkins University |
Mesothelin vaccines and model systems
|
EP2269619A1
(en)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
Methods and compositions concerning poxviruses and cancer
|
US20080019992A1
(en)
*
|
2002-09-02 |
2008-01-24 |
Christoph Zielinski |
Antigen mimotopes and vaccine against cancerous diseases
|
CN1497255A
(en)
*
|
2002-10-02 |
2004-05-19 |
���µ�����ҵ��ʽ���� |
Sampling element for tested body, tested body processing device and its processing method
|
US20040089615A1
(en)
*
|
2002-11-12 |
2004-05-13 |
Alan Weiss |
Evaporation control device for multiwell plates
|
GB2424273B
(en)
*
|
2002-11-14 |
2007-06-27 |
Univ Nottingham |
Method for preparing tumour marker protein
|
US20040258685A1
(en)
*
|
2002-11-21 |
2004-12-23 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
|
WO2004061105A1
(en)
|
2003-01-03 |
2004-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Rhesus her2/neu, nucleotides encoding same, and uses thereof
|
CA2514058C
(en)
*
|
2003-01-24 |
2014-05-13 |
Agensys, Inc. |
Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
|
KR20060002793A
(en)
*
|
2003-03-03 |
2006-01-09 |
더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Methods and compositions involving mda-7
|
CA2522812C
(en)
|
2003-04-18 |
2012-08-21 |
Idm Pharma, Inc. |
Hla-a2 tumor associated antigen peptides and compositions
|
US20050239088A1
(en)
*
|
2003-05-16 |
2005-10-27 |
Shepard H M |
Intron fusion proteins, and methods of identifying and using same
|
US7178491B2
(en)
*
|
2003-06-05 |
2007-02-20 |
Caterpillar Inc |
Control system and method for engine valve actuator
|
WO2004112825A2
(en)
*
|
2003-06-17 |
2004-12-29 |
Mannkind Corporation |
Combinations of tumor-associated antigens for the treatment of various types of cancers
|
CN101173282B
(en)
*
|
2003-07-21 |
2011-04-06 |
P.安杰莱蒂分子生物学研究所 |
Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
|
GB0321615D0
(en)
|
2003-09-15 |
2003-10-15 |
Glaxo Group Ltd |
Improvements in vaccination
|
AU2004285468B2
(en)
|
2003-10-22 |
2011-02-24 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
|
EP2486933B1
(en)
|
2003-11-06 |
2015-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds conjugated with antibodies
|
US8034790B2
(en)
*
|
2003-12-01 |
2011-10-11 |
Introgen Therapeutics |
Use of MDA-7 to inhibit pathogenic infectious organisms
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
US20060286102A1
(en)
*
|
2004-05-14 |
2006-12-21 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
EP2471924A1
(en)
|
2004-05-28 |
2012-07-04 |
Asuragen, INC. |
Methods and compositions involving microRNA
|
CN114053429A
(en)
|
2004-06-01 |
2022-02-18 |
健泰科生物技术公司 |
Antibody-drug conjugates and methods
|
US20110104186A1
(en)
|
2004-06-24 |
2011-05-05 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
CA2571421A1
(en)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Compounds for immunopotentiation
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
NZ553500A
(en)
|
2004-09-23 |
2009-11-27 |
Genentech Inc Genentech Inc |
Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
|
AU2005294347A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
CA2582713A1
(en)
*
|
2004-10-06 |
2006-04-20 |
Wellstat Biologics Corporation |
Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment
|
ES2534303T3
(en)
|
2004-11-12 |
2015-04-21 |
Asuragen, Inc. |
Procedures and compositions involving miRNA and miRNA inhibitor molecules
|
US20060115862A1
(en)
*
|
2004-11-17 |
2006-06-01 |
Duke University |
Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
|
CN100381460C
(en)
*
|
2004-11-30 |
2008-04-16 |
北京市肿瘤防治研究所 |
HER-2 analogue antigen epitope and peptide containing said epitope
|
AU2005321904B2
(en)
*
|
2004-12-29 |
2012-07-12 |
Mannkind Corporation |
Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
|
CN101166539B
(en)
*
|
2005-02-08 |
2012-01-04 |
得克萨斯大学体系董事会 |
Compositions and methods involving MDA-7 for the treatment of cancer
|
US8822535B2
(en)
*
|
2005-04-20 |
2014-09-02 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
|
CN100398558C
(en)
*
|
2005-05-10 |
2008-07-02 |
中国人民解放军军事医学科学院基础医学研究所 |
Active segment of HER2/neu with Herstatin interaction, coding gene and application thereof
|
WO2006124700A2
(en)
*
|
2005-05-12 |
2006-11-23 |
Introgen Therapeutics, Inc. |
P53 vaccines for the treatment of cancers
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
GB2426581A
(en)
*
|
2005-05-27 |
2006-11-29 |
Univ Nottingham |
Immunoassay methods
|
NZ563466A
(en)
|
2005-05-27 |
2009-12-24 |
Oncimmune Ltd |
Improved immunoassay methods
|
AU2006261342B2
(en)
*
|
2005-06-15 |
2012-02-02 |
The Ohio State University Research Foundation |
Her-2 peptides
|
CA2612516C
(en)
|
2005-06-17 |
2015-03-24 |
Mannkind Corporation |
Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
|
GB0512751D0
(en)
*
|
2005-06-22 |
2005-07-27 |
Glaxo Group Ltd |
New adjuvant
|
EP1933864A4
(en)
*
|
2005-09-07 |
2009-12-16 |
Receptor Logic Ltd |
Antibodies as t cell receptor mimics, methods of production and uses thereof
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
JP2009507853A
(en)
*
|
2005-09-07 |
2009-02-26 |
ジェンネレックス インコーポレイティッド |
Systemic treatment of metastatic and / or systemic disseminated cancer using GM-CSF expressing poxvirus
|
EP3195877A1
(en)
*
|
2005-09-08 |
2017-07-26 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Targeted identification of immunogenic peptides
|
US8945573B2
(en)
|
2005-09-08 |
2015-02-03 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Targeted identification of immunogenic peptides
|
WO2007047749A1
(en)
|
2005-10-18 |
2007-04-26 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and systemic immunizations with alphavirus replicon particles
|
TWI457133B
(en)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
Novel composition
|
US20090053221A1
(en)
*
|
2006-01-17 |
2009-02-26 |
Cheung Nai-Kong V |
Immune response enhancing glucan
|
US8323644B2
(en)
*
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
JP2009528267A
(en)
*
|
2006-01-17 |
2009-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
Glucan to enhance treatment
|
WO2007092944A2
(en)
*
|
2006-02-08 |
2007-08-16 |
Introgen Therapeutics, Inc. |
Compositions and methods involving gene therapy and proteasome modulation
|
ES2388556T3
(en)
*
|
2006-03-23 |
2012-10-16 |
Novartis Ag |
Immunopotentiating compounds
|
EP2357184B1
(en)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazoquinoxaline compounds as immunomodulators
|
CA2647100A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
US7517270B2
(en)
*
|
2006-05-30 |
2009-04-14 |
Minds-I, Inc. |
Construction system
|
WO2008042495A2
(en)
|
2006-07-21 |
2008-04-10 |
Life Technologies Corporation |
Sharply resolving labeled protein molecular weight standards
|
US7972602B2
(en)
*
|
2006-08-11 |
2011-07-05 |
Dendreon Corporation |
Promiscuous HER-2/Neu CD4 T cell epitopes
|
CN101632020B
(en)
*
|
2006-09-13 |
2013-11-27 |
昂西免疫有限公司 |
Improved immunoassay methods
|
ES2551892T3
(en)
|
2006-09-15 |
2015-11-24 |
Ottawa Health Research Institute |
Oncolytic rhabdovirus
|
WO2008036776A2
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
|
US20080075528A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Michael Marzetta |
Construction system
|
CA2700573C
(en)
*
|
2006-09-26 |
2016-11-22 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
US8871211B2
(en)
*
|
2006-09-28 |
2014-10-28 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
US20080131878A1
(en)
*
|
2006-12-05 |
2008-06-05 |
Asuragen, Inc. |
Compositions and Methods for the Detection of Small RNA
|
CA2671194A1
(en)
*
|
2006-12-08 |
2008-06-19 |
Asuragen, Inc. |
Mir-20 regulated genes and pathways as targets for therapeutic intervention
|
US7935350B2
(en)
*
|
2006-12-14 |
2011-05-03 |
Antigen Express, Inc. |
Ii-key/Her-2/neu hybrid cancer vaccine
|
US8889143B2
(en)
|
2006-12-14 |
2014-11-18 |
Antigen Express, Inc. |
Ii-key/HER-2/neu hybrid cancer vaccine
|
US7410225B1
(en)
*
|
2007-03-14 |
2008-08-12 |
Minds-I, Inc. |
Multi-part links for endless track
|
KR20080084528A
(en)
*
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
Oncolytic vaccinia virus cancer therapy
|
CN101663584A
(en)
*
|
2007-04-19 |
2010-03-03 |
威尔斯达特生物制剂公司 |
Detection her-2/neu protein from non-isolated circulating cancer cells and treatment
|
DK2162149T3
(en)
|
2007-06-01 |
2014-02-10 |
Jackson H M Found Military Med |
Vaccine for the prevention of breast cancer relapse
|
US20090017716A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Michael Marzetta |
Construction system
|
US20090061456A1
(en)
*
|
2007-08-30 |
2009-03-05 |
Allard William J |
Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells
|
US8361714B2
(en)
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
US20090117532A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Doyle Gerald V |
Pre-clinical method for monitoring serial changes in circulating breast cancer cells in mice
|
WO2009059450A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Shanghai Jiaotong University |
Peptide ligand directed drug delivery
|
US7841923B2
(en)
*
|
2007-11-13 |
2010-11-30 |
Minds-I, Inc. |
Vehicle axle joint for a toy vehicle
|
BRPI0819854B1
(en)
*
|
2007-11-27 |
2019-06-04 |
Veridex, Llc |
A method for isolating, enriching and analyzing circulating melanoma cells in a blood sample
|
US8071562B2
(en)
|
2007-12-01 |
2011-12-06 |
Mirna Therapeutics, Inc. |
MiR-124 regulated genes and pathways as targets for therapeutic intervention
|
US20090191535A1
(en)
*
|
2007-12-22 |
2009-07-30 |
Mark Carle Connelly |
Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells
|
GB0725239D0
(en)
*
|
2007-12-24 |
2008-02-06 |
Oncimmune Ltd |
Calibrator for autoantibody assay
|
WO2009137807A2
(en)
|
2008-05-08 |
2009-11-12 |
Asuragen, Inc. |
Compositions and methods related to mirna modulation of neovascularization or angiogenesis
|
JP2010006705A
(en)
*
|
2008-06-13 |
2010-01-14 |
Atlas Antibodies Ab |
Her2 subset
|
DK2328923T3
(en)
|
2008-09-02 |
2016-03-21 |
Cedars Sinai Medical Center |
CD133 epitopes
|
EP2355843B8
(en)
|
2008-12-10 |
2017-08-02 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Vaccine for the prevention of breast cancer recurrence
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
US20110045080A1
(en)
*
|
2009-03-24 |
2011-02-24 |
William Marsh Rice University |
Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
|
CA2761777A1
(en)
*
|
2009-05-14 |
2010-11-18 |
Prometheus Laboratories Inc. |
Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
|
WO2010144874A2
(en)
|
2009-06-12 |
2010-12-16 |
University Of Southern California |
Clusterin pharmaceuticals and treatment methods using the same
|
WO2011031870A1
(en)
|
2009-09-09 |
2011-03-17 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
BR112012005774B8
(en)
|
2009-09-14 |
2023-02-14 |
Jennerex Inc |
use of an anti-angiogenic kinase inhibitor in cancer treatment
|
MX337062B
(en)
|
2009-12-10 |
2016-02-11 |
Ottawa Hospital Res Inst |
Oncolytic rhabdovirus.
|
WO2011107100A1
(en)
|
2010-03-03 |
2011-09-09 |
Aarhus Universitet |
Methods and compositions for regulation of herv4
|
MX2012011901A
(en)
|
2010-04-15 |
2012-11-29 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof.
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
EP2576613A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
SG10201600791TA
(en)
|
2010-06-08 |
2016-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
US20120121615A1
(en)
|
2010-11-17 |
2012-05-17 |
Flygare John A |
Alaninyl maytansinol antibody conjugates
|
CN103429258B
(en)
|
2011-01-04 |
2016-03-09 |
新罗杰公司 |
By use oncolytic vaccinia virus generate for tumor antigen antibody and generate tumour-specific CDC
|
US9222085B2
(en)
|
2011-02-03 |
2015-12-29 |
Mirna Therapeutics, Inc. |
Synthetic mimics of MIR-124
|
EP2670850B1
(en)
|
2011-02-03 |
2016-10-26 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-34
|
US8679767B2
(en)
|
2011-05-12 |
2014-03-25 |
Genentech, Inc. |
Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
|
ES2627529T3
(en)
|
2011-06-08 |
2017-07-28 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Compositions for glioblastoma treatment
|
DK2739310T3
(en)
|
2011-08-05 |
2018-07-16 |
Res Found Dev |
Improved methods and compositions for modulating OLFML3-mediated angiogenesis
|
CN108434440B
(en)
|
2011-09-06 |
2022-08-23 |
新加坡科技研究局 |
Polypeptide vaccine
|
US9644241B2
(en)
|
2011-09-13 |
2017-05-09 |
Interpace Diagnostics, Llc |
Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
|
JP6104257B2
(en)
|
2011-10-14 |
2017-03-29 |
メドイミューン・リミテッドMedImmune Limited |
Pyrrolobenzodiazepine and its conjugates
|
AU2013221309B2
(en)
|
2012-02-17 |
2017-03-30 |
Mayo Foundation For Medical Education And Research |
Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide
|
WO2013130093A1
(en)
|
2012-03-02 |
2013-09-06 |
Genentech, Inc. |
Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
|
WO2013188873A1
(en)
|
2012-06-15 |
2013-12-19 |
Gencia Corporation |
Compositions and methods for enhancing immune responses
|
UA114108C2
(en)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
|
DK2906253T3
(en)
|
2012-10-12 |
2018-10-22 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine anti-PSMA antibody conjugates
|
WO2014057120A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2014057119A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
MX364327B
(en)
|
2012-10-12 |
2019-04-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine-anti-cd22 antibody conjugates.
|
US10736903B2
(en)
|
2012-10-12 |
2020-08-11 |
Medimmune Limited |
Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
|
ME03486B
(en)
|
2012-10-12 |
2020-01-20 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2014057117A1
(en)
|
2012-10-12 |
2014-04-17 |
Adc Therapeutics Sàrl |
Pyrrolobenzodiazepine-antibody conjugates
|
DK2912064T3
(en)
|
2012-10-24 |
2019-07-22 |
Res Found Dev |
JAM-C ANTIBODIES AND PROCEDURES FOR TREATING CANCER
|
US9567340B2
(en)
|
2012-12-21 |
2017-02-14 |
Medimmune Limited |
Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
|
ES2658888T5
(en)
|
2012-12-21 |
2021-10-19 |
Medimmune Ltd |
Pyrrolobenzodiazepines and their conjugates
|
US20140234351A1
(en)
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd. |
Cancer vaccines and vaccination methods
|
US10363293B2
(en)
|
2013-02-21 |
2019-07-30 |
Turnstone Limited Partnership |
Vaccine composition
|
EP2968585B1
(en)
|
2013-03-13 |
2018-07-18 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
EA027910B1
(en)
|
2013-03-13 |
2017-09-29 |
Медимьюн Лимитед |
Pyrrolobenzodiazepines and conjugates thereof
|
MX364330B
(en)
|
2013-03-13 |
2019-04-23 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof.
|
EA201690195A1
(en)
|
2013-08-12 |
2016-05-31 |
Дженентек, Инк. |
ANTIBODY CONJUGATE CONNECTIONS ON THE BASIS OF DIMER 1- (HLORMETHYL) -2,3-DIGYDRO-1H-BENZO [E] INDOL AND METHODS OF APPLICATION AND TREATMENT
|
CA2921401A1
(en)
|
2013-08-14 |
2015-02-19 |
William Marsh Rice University |
Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
|
CA2921652A1
(en)
|
2013-08-21 |
2015-02-26 |
Manuel A. Riquelme |
Compositions and methods for targeting connexin hemichannels
|
KR102269209B1
(en)
|
2013-08-29 |
2021-06-28 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
|
CN105722522B
(en)
|
2013-08-30 |
2021-10-19 |
得克萨斯大学体系董事会 |
Administration of kynurenine depleting enzymes for tumor therapy
|
EP3054985B1
(en)
|
2013-10-11 |
2018-12-26 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
EP3054983B1
(en)
|
2013-10-11 |
2019-03-20 |
Medimmune Limited |
Pyrrolobenzodiazepine-antibody conjugates
|
US9956299B2
(en)
|
2013-10-11 |
2018-05-01 |
Medimmune Limited |
Pyrrolobenzodiazepine—antibody conjugates
|
GB201317982D0
(en)
|
2013-10-11 |
2013-11-27 |
Spirogen Sarl |
Pyrrolobenzodiazepines and conjugates thereof
|
JP2017501694A
(en)
|
2013-12-04 |
2017-01-19 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
Analysis of genomic DNA, RNA and proteins in exosomes for diagnosis and therapy
|
CA2929565A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
KR20170042495A
(en)
|
2013-12-16 |
2017-04-19 |
제넨테크, 인크. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
CA2928952A1
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
JP7080053B2
(en)
|
2014-08-29 |
2022-06-03 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Administration of kynurenine-depleting enzymes for the treatment of tumors
|
WO2016033105A1
(en)
|
2014-08-29 |
2016-03-03 |
The Board Of Regents Of The University Of Texas System |
Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
JP6622293B2
(en)
|
2014-09-12 |
2019-12-18 |
ジェネンテック, インコーポレイテッド |
Anthracycline disulfide intermediates, antibody-drug conjugates, and methods
|
CN107108724A
(en)
|
2014-09-12 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
Cysteine engineered antibody and conjugate
|
GB201416112D0
(en)
|
2014-09-12 |
2014-10-29 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CR20170099A
(en)
|
2014-09-17 |
2017-07-19 |
Genentech Inc |
PIRROLOBENZODIAZEPINAS AND CONJUGADOS DE ANTIBERPOS-DISULFURO DE LAS SISAS
|
NZ731782A
(en)
|
2014-11-25 |
2023-04-28 |
Medimmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
CN107206101B
(en)
|
2014-12-03 |
2021-06-25 |
基因泰克公司 |
Quaternary ammonium compounds and antibody-drug conjugates thereof
|
CA2976236A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
RU2721953C2
(en)
|
2015-03-04 |
2020-05-25 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Methods of treating cancer, having hemizygous loss of tp53
|
CN107533065A
(en)
*
|
2015-03-13 |
2018-01-02 |
布莱恩·J·赫尔尼奇 |
CD4 is monitored in cancer and immune restoration+The method of 1 type t helper cell response
|
US20180171294A1
(en)
*
|
2015-03-26 |
2018-06-21 |
The Trustees Of The University Of Pennsylvania |
In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
EP3302539A4
(en)
*
|
2015-05-22 |
2018-12-19 |
Brian J. Czerniecki |
Manufacturing multi-dose injection ready dendritic cell vaccines
|
US9993538B2
(en)
|
2015-05-29 |
2018-06-12 |
Galena Biopharma, Inc. |
Peptide vaccine therapy for treatment of FRα-expressing tumors
|
AU2016275046B2
(en)
|
2015-06-10 |
2022-07-28 |
Board Of Regents, The University Of Texas System |
Use of exosomes for the treatment of disease
|
RU2612015C2
(en)
*
|
2015-06-29 |
2017-03-01 |
Общество с ограниченной ответственностью "Сибинтех" |
Peptide-immunogen used in therapeutic vaccine for treatment of metastatic breast cancer of cats and dogs
|
JP6938462B2
(en)
|
2015-07-28 |
2021-09-22 |
ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System |
Implant composition for unidirectional delivery of therapeutic compounds to the brain
|
WO2017040380A2
(en)
|
2015-08-28 |
2017-03-09 |
Research Development Foundation |
Engineered antibody fc variants
|
MA43345A
(en)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
EA038277B1
(en)
|
2015-10-14 |
2021-08-04 |
Байо-Пат Холдингз, Инк. |
P-ethoxy nucleic acids for liposomal formulation
|
MA43354A
(en)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
|
MA45326A
(en)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
RU2624862C2
(en)
*
|
2015-10-20 |
2017-07-07 |
Общество с ограниченной ответственностью "Эпитек" |
Peptide-immunogen used in therapeutic vaccine for metastatic breast cancer treatment
|
WO2017079746A2
(en)
|
2015-11-07 |
2017-05-11 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
|
EP3373968A4
(en)
|
2015-11-09 |
2019-06-26 |
The Children's Hospital of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
MX2018006613A
(en)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof.
|
KR20180100122A
(en)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor)
|
GB201601431D0
(en)
|
2016-01-26 |
2016-03-09 |
Medimmune Ltd |
Pyrrolobenzodiazepines
|
GB201602356D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
GB201602359D0
(en)
|
2016-02-10 |
2016-03-23 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
CA3015839A1
(en)
|
2016-02-26 |
2017-08-31 |
The Board Of Regents Of The University Of Texas System |
Connexin (cx)43 hemichannel-binding antibodies and uses thereof
|
CA3016457A1
(en)
|
2016-03-02 |
2017-09-08 |
The Board Of Regents Of The University Of Texas System |
Sting activating nanovaccine for immunotherapy
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
KR20230031373A
(en)
|
2016-03-29 |
2023-03-07 |
주식회사 에스티큐브앤컴퍼니 |
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
|
JP7241541B2
(en)
|
2016-03-29 |
2023-03-17 |
エスティーキューブ,インコーポレイテッド |
Bifunctional antibodies specific for glycosylated PD-L1 and methods of use thereof
|
WO2017176076A1
(en)
|
2016-04-06 |
2017-10-12 |
Ewha University - Industry Collaboration Foundation |
A peptide with ability to penetrate cell membrane
|
BR112018072286A2
(en)
|
2016-04-29 |
2019-02-12 |
Yale University |
targeted measure of hormone receptor-related transcriptional activity
|
GB201607478D0
(en)
|
2016-04-29 |
2016-06-15 |
Medimmune Ltd |
Pyrrolobenzodiazepine Conjugates
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
CN109313200B
(en)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
Bioanalytical methods for characterizing site-specific antibody-drug conjugates
|
MA45169A
(en)
|
2016-05-31 |
2019-04-10 |
Sellas Life Sciences Group Inc |
VACCINE THERAPY FOR THE TREATMENT OF ENDOMETRIC AND OVARIAN CANCER
|
EP3464560A4
(en)
*
|
2016-06-03 |
2020-01-15 |
Etubics Corporation |
Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
BR112019000215A2
(en)
|
2016-07-06 |
2019-04-24 |
Board Of Regents, The University Of Texas System |
human enzyme-mediated cystine depletion
|
WO2018017673A1
(en)
|
2016-07-20 |
2018-01-25 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
WO2018035429A1
(en)
|
2016-08-18 |
2018-02-22 |
Wisconsin Alumni Research Foundation |
Peptides that inhibit syndecan-1 activation of vla-4 and igf-1r
|
ES2928654T3
(en)
|
2016-09-16 |
2022-11-21 |
Bio Path Holdings Inc |
Combination therapy with liposomal antisense oligonucleotides
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
WO2018089423A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
KR20190112263A
(en)
|
2016-12-12 |
2019-10-04 |
멀티비르 인코포레이티드 |
Methods and compositions comprising viral gene therapy and immune checkpoint inhibitors for the treatment and prevention of cancer and infectious diseases
|
NZ754810A
(en)
|
2017-02-08 |
2023-04-28 |
Medimmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
WO2018156973A1
(en)
|
2017-02-24 |
2018-08-30 |
Board Of Regents, The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
SI3612537T1
(en)
|
2017-04-18 |
2022-10-28 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
US20200129637A1
(en)
|
2017-04-20 |
2020-04-30 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
CN110603324A
(en)
|
2017-05-12 |
2019-12-20 |
得克萨斯大学体系董事会 |
Human enzyme-mediated homocysteine depletion for the treatment of patients with hyperhomocysteinemia and homocystinuria
|
WO2018209211A1
(en)
|
2017-05-12 |
2018-11-15 |
Board Of Regents, The University Of Texas System |
Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
|
KR20200024158A
(en)
|
2017-05-31 |
2020-03-06 |
주식회사 에스티큐브앤컴퍼니 |
How to treat cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
EP3630835A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
KR20200026209A
(en)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand
|
UA127900C2
(en)
|
2017-06-14 |
2024-02-07 |
Ейдісі Терапьютікс Са |
Dosage regimes for the administration of an anti-cd19 adc
|
HRP20220311T1
(en)
|
2017-08-18 |
2022-05-13 |
Medimmune Limited |
Pyrrolobenzodiazepine conjugates
|
US10301319B2
(en)
|
2017-09-20 |
2019-05-28 |
Ph Pharma Co., Ltd. |
Thailanstatin analogs
|
EP4116327A1
(en)
|
2017-10-11 |
2023-01-11 |
Board Of Regents, The University Of Texas System |
Human pd-l1 antibodies and methods of use therefor
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
JP2021518408A
(en)
|
2018-03-19 |
2021-08-02 |
マルチビア インコーポレイテッド |
Methods and Compositions Containing Tumor Suppressor Gene Therapies and CD122 / CD132 Agonists for Cancer Treatment
|
WO2019182896A1
(en)
|
2018-03-23 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
CN108624589B
(en)
*
|
2018-04-17 |
2021-12-17 |
广州永诺生物科技有限公司 |
Circular RNA circ-ERBB2, detection reagent and application thereof
|
CN108715603A
(en)
*
|
2018-06-08 |
2018-10-30 |
天津亨佳生物科技发展有限公司 |
A kind of Antigenic Peptide chain group for treating tumour and its application in drug
|
CN108484732A
(en)
*
|
2018-06-08 |
2018-09-04 |
天津亨佳生物科技发展有限公司 |
A kind of Antigenic Peptide chain group for treating tumour and its application in drug
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
EP3870235A1
(en)
|
2018-10-24 |
2021-09-01 |
F. Hoffmann-La Roche AG |
Conjugated chemical inducers of degradation and methods of use
|
WO2020106621A1
(en)
|
2018-11-19 |
2020-05-28 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
AU2019386140A1
(en)
|
2018-11-28 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
CA3121210A1
(en)
|
2018-11-29 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
JP2022513198A
(en)
|
2018-12-10 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
EP3920889A4
(en)
|
2019-02-08 |
2022-12-07 |
Board of Regents, The University of Texas System |
Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
|
KR20220007879A
(en)
|
2019-05-09 |
2022-01-19 |
후지필름 셀룰러 다이내믹스, 인코포레이티드 |
How to generate hepatocytes
|
TW202110431A
(en)
|
2019-05-17 |
2021-03-16 |
美商癌症預防製藥股份有限公司 |
Methods for treating familial adenomatous polyposis
|
CN114555807A
(en)
|
2019-07-19 |
2022-05-27 |
费城儿童医院 |
Chimeric antigen receptor comprising glypican 2 binding domain
|
AU2020344675A1
(en)
|
2019-09-13 |
2022-03-31 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
US20220411511A1
(en)
|
2019-09-26 |
2022-12-29 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
US20220356248A1
(en)
|
2019-10-09 |
2022-11-10 |
Stcube & Co |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
WO2021087458A2
(en)
|
2019-11-02 |
2021-05-06 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
WO2021141977A1
(en)
|
2020-01-07 |
2021-07-15 |
Board Of Regents, The University Of Texas System |
Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy
|
WO2021167908A1
(en)
|
2020-02-17 |
2021-08-26 |
Board Of Regents, The University Of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
TW202208418A
(en)
|
2020-05-21 |
2022-03-01 |
美國德州系統大學評議委員會 |
T cell receptors with vgll1 specificity and uses thereof
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
US20230266325A1
(en)
|
2020-06-30 |
2023-08-24 |
Lunglife Ai, Inc. |
Methods for detecting lung cancer
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
WO2022104109A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
WO2022115611A1
(en)
|
2020-11-25 |
2022-06-02 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
EP4281116A1
(en)
|
2021-01-19 |
2023-11-29 |
William Marsh Rice University |
Bone-specific delivery of polypeptides
|
GB2603166A
(en)
|
2021-01-29 |
2022-08-03 |
Thelper As |
Therapeutic and Diagnostic Agents and Uses Thereof
|
CA3228262A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
CN115925875A
(en)
*
|
2021-08-20 |
2023-04-07 |
百奥赛图(北京)医药科技股份有限公司 |
HER2 gene humanized non-human animal and construction method and application thereof
|
WO2023060136A1
(en)
|
2021-10-05 |
2023-04-13 |
Cytovia Therapeutics, Llc |
Natural killer cells and methods of use thereof
|
CN113699221B
(en)
*
|
2021-10-19 |
2023-10-10 |
广州吉赛医疗科技有限公司 |
HER2 mRNA and annular RNA multiplex fluorescence quantitative PCR detection primer probe and application thereof
|
WO2023068382A2
(en)
|
2021-10-20 |
2023-04-27 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
CN114262689A
(en)
*
|
2021-12-17 |
2022-04-01 |
上海纳米技术及应用国家工程研究中心有限公司 |
Method for rapidly detecting activity of CD19/CD20-CAR-T cells
|
GB202201137D0
(en)
|
2022-01-28 |
2022-03-16 |
Thelper As |
Therapeutic and diagnostic agents and uses thereof
|
WO2023172514A1
(en)
|
2022-03-07 |
2023-09-14 |
Catamaran Bio, Inc. |
Engineered immune cell therapeutics targeted to her2 and methods of use thereof
|
WO2023192976A1
(en)
|
2022-04-01 |
2023-10-05 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023230531A1
(en)
|
2022-05-24 |
2023-11-30 |
Lunglife Ai, Inc. |
Methods for detecting circulating genetically abnormal cells
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|